{"id":"obv-ptv-r","safety":{"commonSideEffects":[{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ombitasvir is a NS5A inhibitor that works by binding to the NS5A protein of the hepatitis C virus, preventing the virus from replicating. Paritaprevir is a protease inhibitor that works by binding to the NS3/4A protease of the hepatitis C virus, preventing the virus from replicating. Ritonavir is a protease inhibitor that is used in combination with other medications to increase their effectiveness and reduce the risk of resistance.","oneSentence":"Ombitasvir/paritaprevir/ritonavir is a combination of a protease inhibitor and a non-nucleoside NS5A inhibitor used to treat hepatitis C virus infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:48.798Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"},{"name":"Genotype 1, 2, 4, 5, or 6 infection"}]},"trialDetails":[{"nctId":"NCT03003338","phase":"PHASE4","title":"MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2017-10-24","conditions":"Hepatitis C, Chronic","enrollment":5},{"nctId":"NCT02023112","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01","conditions":"Hepatitis C Virus","enrollment":171},{"nctId":"NCT02707952","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-02-22","conditions":"Chronic Hepatitis C Virus, Hepatitis C Virus","enrollment":295},{"nctId":"NCT02292719","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-12-19","conditions":"Chronic Hepatitis C Virus Infection","enrollment":70},{"nctId":"NCT04391985","phase":"PHASE1, PHASE2","title":"Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-03-01","conditions":"Chronic Hepatitis C Virus Infection","enrollment":113},{"nctId":"NCT04378608","phase":"PHASE1, PHASE2","title":"Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2017-01-05","conditions":"Hepatitis C Virus Infection","enrollment":100},{"nctId":"NCT03499639","phase":"PHASE4","title":"Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease","status":"COMPLETED","sponsor":"Assiut University","startDate":"2018-05-01","conditions":"End-stage Renal Disease, HCV Coinfection","enrollment":110},{"nctId":"NCT03050905","phase":"PHASE4","title":"Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2017-06-22","conditions":"HCV Coinfection","enrollment":7},{"nctId":"NCT02874066","phase":"PHASE4","title":"PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2017-03-13","conditions":"Hepatitis Viruses","enrollment":46},{"nctId":"NCT03710252","phase":"PHASE4","title":"A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study","status":"COMPLETED","sponsor":"American Research Corporation","startDate":"2016-03","conditions":"Chronic Hepatitis C","enrollment":100},{"nctId":"NCT02023099","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-12","conditions":"Chronic Hepatitis C Infection","enrollment":363},{"nctId":"NCT02504099","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma","status":"TERMINATED","sponsor":"AbbVie","startDate":"2015-07","conditions":"Chronic Hepatitis C Infection","enrollment":3},{"nctId":"NCT02487199","phase":"PHASE3","title":"Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-09-30","conditions":"Hepatitis C Virus (HCV)","enrollment":18},{"nctId":"NCT01782495","phase":"PHASE2","title":"A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients","status":"COMPLETED","sponsor":"AbbVie","startDate":"2013-02-25","conditions":"Chronic Hepatitis C Infection","enrollment":129}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":83,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-267 also known as ombitasvir","ABT-450 also known as paritaprevir","ritonavir (r) also known as Norvir","VIEKIRAX combination tablets","TECHNIVIE"],"phase":"phase_3","status":"active","brandName":"OBV/PTV/r","genericName":"OBV/PTV/r","companyName":"AbbVie","companyId":"abbvie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ombitasvir/paritaprevir/ritonavir is a combination of a protease inhibitor and a non-nucleoside NS5A inhibitor used to treat hepatitis C virus infection. Used for Chronic hepatitis C virus infection, Genotype 1, 2, 4, 5, or 6 infection.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-07-24T00:00:00.000Z","mah":"ABBVIE","brand_name_local":"TECHNIVIE","application_number":"NDA207931"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}